Background context:

Perioperative antibiotics are critical in reducing the risk of postoperative spine infections. However, the efficacy and optimal weight-based prophylactic cefazolin dosing is unclear.

Purpose:

To determine 1) if inadequate weight-based prophylactic dosing of cefazolin affects infection rates after spinal fusions and 2) identify the optimal dosing of cefazolin.

Study design/setting:

Single center retrospective cohort PATIENT SAMPLE: Patients undergoing posterior cervical or lumbar spinal fusion between January 2000 and October 2020 OUTCOME MEASURES: Postoperative surgical site infection status METHODS: Patients were grouped based on our institutionally derived dosing adequacy standards, 1g for <60kg, 2g for 60-120kg, and 3g for >120kg. Univariate comparisons and multivariate regressions identified the effect of inadequate dosing on infection rate. Patients were subsequently regrouped into cefazolin dose (grams) administered and logistic regression and receiver operating characteristic curves (ROC) were compiled to determine the probability of infection based on cefazolin dose and patient weight. Alpha was set at 0.05.

Results:

A total of 2,643 patients met inclusion criteria and 95 infections (3.6%) were identified. The infection rate was higher in the inadequate dosing group (5.86% vs. 2.58%, p<0.001). Adequate dosing was a predictor of decreased infections after lumbar fusion (OR: 0.43, p<0.001), but not posterior cervical fusions (OR: 0.47, p=0.065). Patients were subsequently regrouped into one or two grams of cefazolin administered resulting in a 5.01% and 2.77% infection rate, respectively (p=0.005). The area under the curve (AUC) and 95% confidence interval for one [0.850 (0.777-0.924)] and two [0.575 (0.493-0.657)] grams of cefazolin demonstrated lower infection rates for patients given two grams cefazolin.

Conclusions:

Patients receiving an inadequate weight-based dose of preoperative cefazolin had an increased risk of infection following spinal fusion surgery. Two grams prophylactic cefazolin significantly reduces the likelihood of infection.